GlobeNewswire Clinical StudiesOriginal article
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
Data ReadoutpositiveSAT-3247Positive
AI Analysis
Summary
Satellos Bioscience announced positive six-month interim data from the TRAILHEAD trial of SAT-3247 in adults with Duchenne muscular dystrophy, demonstrating reduced muscle fat fraction, stable strength, and a favorable safety profile.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Six-month interim TRAILHEAD data showing reduced muscle fat fraction, increased effort, stable strength, lower CK and favorable safety profile in DMD adults
Importance:7/10
Sentiment:
0.75
DMDDuchenne muscular dystrophySAT-3247TRAILHEADclinical trialinterim datamuscle disease
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 8, 2026 10:30 AM